Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “hold” rating restated by research analysts at Cann in a report issued on Tuesday, April 17th.
The analysts wrote, “While we have not modeled any revenue impact from AG-270 to either Agios or Celgene by 2022, we believe that AG-270 could be an important value driver for Agios and Celgene. AG-270 is a novel compound in the field of synthetic lethality, and has the potential to address large patient populations. We are not making any changes to our outlook at this time, but we continue to watch the timing of the program closely.””
AGIO has been the topic of a number of other reports. Oppenheimer cut Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. They noted that the move was a valuation call. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a research report on Tuesday, January 16th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub raised Agios Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. Finally, Royal Bank of Canada lifted their price objective on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $87.00.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same period in the previous year, the business posted ($1.34) earnings per share. The company’s revenue for the quarter was down 56.7% on a year-over-year basis. research analysts predict that Agios Pharmaceuticals will post -6.25 EPS for the current year.
In related news, insider Steven L. Hoerter sold 2,050 shares of the business’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $84.65, for a total value of $173,532.50. Following the transaction, the insider now directly owns 2,050 shares of the company’s stock, valued at approximately $173,532.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Christopher Bowden sold 2,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 12th. The stock was sold at an average price of $85.10, for a total value of $170,200.00. Following the completion of the sale, the insider now directly owns 2,881 shares in the company, valued at approximately $245,173.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 134,880 shares of company stock worth $10,790,918. 5.43% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB bought a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $259,000. Alkeon Capital Management LLC increased its stake in Agios Pharmaceuticals by 12.0% in the 4th quarter. Alkeon Capital Management LLC now owns 511,619 shares of the biopharmaceutical company’s stock worth $29,250,000 after acquiring an additional 54,858 shares during the last quarter. Teachers Advisors LLC increased its stake in Agios Pharmaceuticals by 13.5% in the 4th quarter. Teachers Advisors LLC now owns 53,591 shares of the biopharmaceutical company’s stock worth $3,064,000 after acquiring an additional 6,375 shares during the last quarter. HBK Investments L P bought a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $306,000. Finally, Two Sigma Investments LP increased its stake in Agios Pharmaceuticals by 18.8% in the 4th quarter. Two Sigma Investments LP now owns 53,265 shares of the biopharmaceutical company’s stock worth $3,045,000 after acquiring an additional 8,434 shares during the last quarter. 82.41% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://weekherald.com/2018/04/24/cann-reaffirms-hold-rating-for-agios-pharmaceuticals-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.